Earnings Estimate Revisions for Nevro This maker of an electrical implant that treats leg and back pain is expected to earn -$2.40 per share for the fiscal year ending December 2024, which ...

Nevro (NVRO) shares ended the last trading session 13.9% higher at $5.72. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...

The maker of an electrical implant that treats leg and back pain posted revenue of $101.9 million in the period, also beating Street forecasts. Seven analysts surveyed by Zacks expected $98.4 million.

This was also ~18% of the company's permanent implant volumes. It pulled this to another operating loss of $25.8mm and a net loss of $0.69/share, flat on Q2 FY'22.

Nevro. Corp. closed the acquisition of privately held Vyrsa Technologies Inc., adding the company’s V1 implant for sacroiliac (SI) joint fusion to its product line for chronic pain. Nevro paid $40 ...

Nevro is a company that has developed a spinal cord stimulation implant to treat chronic pain. See why I will remain on the sidelines on NVRO stock for now.

Pain management company Nevro Corp NVRO reported Q2 FY23 revenue of $108.8 million, up 4% Y/Y, missing the management guidance of $110 million-$112 million and consensus of $109.33 million.

Earnings Estimate Revisions for Nevro This maker of an electrical implant that treats leg and back pain is expected to earn -$2.40 per share for the fiscal year ending December 2024, which ...

Financial Position Nevro exited second-quarter 2022 with cash and cash equivalents, and short-term investments of $310.8 million compared with $323.6 million at the end of first quarter. Long-term ...

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Nevro Corp. (NVRO) on Tuesday reported a loss of $53.1 million in its fourth quarter. On a per-share basis, the Redwood City… ...